|
Jackson Laboratory
tsc1 fl fl mice ![]() Tsc1 Fl Fl Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/tsc1 fl fl mice/product/Jackson Laboratory Average 86 stars, based on 1 article reviews
tsc1 fl fl mice - by Bioz Stars,
2026-06
86/100 stars
|
Buy from Supplier |
|
Jackson Laboratory
tuberous sclerosis complex tsc1 knockdown ![]() Tuberous Sclerosis Complex Tsc1 Knockdown, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/tuberous sclerosis complex tsc1 knockdown/product/Jackson Laboratory Average 86 stars, based on 1 article reviews
tuberous sclerosis complex tsc1 knockdown - by Bioz Stars,
2026-06
86/100 stars
|
Buy from Supplier |
|
The Human TSC1 Alexa Fluor« 594 conjugated Antibody from R D Systems is a mouse monoclonal antibody to TSC1 This antibody reacts with human The Human TSC1 Alexa Fluor« 594 conjugated Antibody has been validated
|
Buy from Supplier |
|
The TSC1 Antibody (488915) [Alexa Fluor® 532] from Novus is a TSC1 antibody to TSC1. This antibody reacts with Human. The TSC1 antibody has been validated for the following applications: Western Blot, Intracellular Staining by
|
Buy from Supplier |
|
The TSC1 Antibody [mFluor Violet 450 SE] from Novus is a TSC1 antibody to TSC1. This antibody reacts with Human, Mouse, Rat. The TSC1 antibody has been validated for the following applications: Western Blot, ELISA,
|
Buy from Supplier |
|
Hamartin, or TSC1, is a suspected tumor suppressor implicated in the disease tuberous sclerosis 1. It is a negative regulator of cell division controlling the transition from G0/G1 to S phase, and it seems to
|
Buy from Supplier |
|
The Human TSC1 Alexa Fluor® 488-conjugated Antibody from R&D Systems is a TSC1 antibody to TSC1. This antibody reacts with Human. The TSC1 antibody has been validated for the following applications: Intracellular Staining by Flow
|
Buy from Supplier |
|
The TSC1 Antibody (OTI3A2) [Alexa Fluor® 647] from Novus is a TSC1 antibody to TSC1. This antibody reacts with Human, Mouse, Rat. The TSC1 antibody has been validated for the following applications: Western Blot, Immunohistochemistry.
|
Buy from Supplier |
|
The TSC1 Antibody [Alexa Fluor® 350] from Novus is a TSC1 antibody to TSC1. This antibody reacts with Human, Mouse, Rat. The TSC1 antibody has been validated for the following applications: Western Blot, ELISA, Immunocytochemistry/
|
Buy from Supplier |
|
The TSC1 Antibody [Alexa Fluor® 647] from Novus is a TSC1 antibody to TSC1. This antibody reacts with Human, Mouse, Rat. The TSC1 antibody has been validated for the following applications: Western Blot, ELISA, Immunocytochemistry/
|
Buy from Supplier |
|
The TSC1 Antibody [Janelia Fluor® 549] from Novus is a TSC1 antibody to TSC1. This antibody reacts with Human, Mouse. The TSC1 antibody has been validated for the following applications: Western Blot, Immunoprecipitation.
|
Buy from Supplier |
Image Search Results
Journal: iScience
Article Title: Regulatory role of mTORC1 signaling in osteoblasts in acute myeloid leukemia progression and steady-state hematopoiesis
doi: 10.1016/j.isci.2025.114533
Figure Lengend Snippet: mTORC1 activation in osteoblasts accelerates AML progression (A) Schematic diagram of generation of tissue-specific Tsc1 knockout mice. (B) Schematic diagram of generation of a MLL-AF9 murine AML model. (C and D) Representative flow cytometry plots and percentages of GFP + AML cells in the (C) peripheral blood ( n = 7–9) and (D) bone marrow ( n = 11) of Tsc1 fl/fl and Col1a1-Cre;Tsc1 fl/fl mice. (E–G) Representative flow cytometry plots and percentages of (E) GFP + c-Kit – AML cells and GFP + c-Kit + AML cells ( n = 6–7), (F) BrdU + GFP + c-Kit + AML cells ( n = 4–5), and (G) Annexin V + GFP + c-Kit + AML cells ( n = 4–5) in the bone marrow of Tsc1 fl/fl and Col1a1-Cre;Tsc1 fl/fl mice. (H) Percentages of GFP + AML cells in the peripheral blood and bone marrow of Tsc1 fl/fl and Col1a1-Cre;Tsc1 fl/fl mice 8 days after the second transplantation ( n = 3). (I and J) Survival probabilities of (I) Tsc1 fl/fl and Col1a1-Cre;Tsc1 fl/fl AML mice ( n = 6–7) and (J) WT AML mice transplanted with c-Kit + AML cells from Raptor fl/fl and Col1a1-Cre;Raptor fl/fl mice ( n = 5–7). All mice used in this study were male. n.s., not significant. ∗ p < 0.05. Error bars show the standard deviation.
Article Snippet:
Techniques: Activation Assay, Knock-Out, Flow Cytometry, Transplantation Assay, Standard Deviation
Journal: iScience
Article Title: Regulatory role of mTORC1 signaling in osteoblasts in acute myeloid leukemia progression and steady-state hematopoiesis
doi: 10.1016/j.isci.2025.114533
Figure Lengend Snippet: Activation of mTORC1 in osteoblasts impairs normal hematopoiesis (A) Schematic diagram of flow cytometric analysis of Tsc1 fl/fl and Col1a1-Cre;Tsc1 fl/fl mice. (B) The number of BM-MNCs in hind legs of Tsc1 fl/fl and Col1a1-Cre;Tsc1 fl/fl mice ( n = 9–10). (C–F) Representative flow cytometry plots and percentages of (C) LSK cells and LSK subpopulations ( n = 17–18), (D) LK cells and LK subpopulations ( n = 14–15), (E) CD11b + Gr-1 + myeloid cells ( n = 15–16), and (F) B220 + IgM – immature and B220 + IgM + mature B cells ( n = 16–18) in the bone marrow of Tsc1 fl/fl and Col1a1-Cre;Tsc1 fl/fl mice. (G) Representative flow cytometry plots and fold changes in the percentage of LSK cells ( n = 7–18), CD11b + Gr-1 + myeloid cells ( n = 5–18), and B220 + IgM – immature and B220 + IgM + mature B cells ( n = 5–16) in the bone marrow of Tsc1 fl/fl , Col1a1-Cre;Tsc1 fl/fl , and Col1a1-Cre;Tsc1 fl/fl ;Raptor fl/+ mice. All mice used in this study were male. n.s., not significant. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, # p < 0.05, ## p < 0.01, and ### p < 0.001. Error bars show the standard deviation.
Article Snippet:
Techniques: Activation Assay, Flow Cytometry, Standard Deviation
Journal: iScience
Article Title: Regulatory role of mTORC1 signaling in osteoblasts in acute myeloid leukemia progression and steady-state hematopoiesis
doi: 10.1016/j.isci.2025.114533
Figure Lengend Snippet: IL-6 in osteoblasts plays a crucial role for AML progression (A) Schematic diagram of three datasets used to screen for factors involved in the cell-cell interaction between mTORC1-activated osteoblasts and AML cells. (B and C) Volcano plots showing DEGs (B) in osteoblasts co-cultured with AML cells compared to monocultured osteoblasts and (C) in mTORC1 high osteoblasts compared to mTORC1 low osteoblasts. (D) Venn diagram highlighting overlapping genes identified across the three datasets. (E) Il6 mRNA expression in calvarial osteoblasts from Col1a1-Cre;Tsc1 fl/fl mice ( n = 4–5). (F) GSEA results for the HALLMARK_IL6_JAK_STAT3_SIGNALING gene set in AML cells co-cultured with osteoblasts. (G) MFI of phosphorylated STAT3 in AML cells in the murine AML model and in lineage – cells from WT mice ( n = 4–5). (H) Schematic diagram of generation of the IL-6R-knockdown MLL-AF9 murine AML model. (I) Survival probabilities of Tsc1 fl/fl and Col1a1-Cre;Tsc1 fl/fl mice transplanted with shCtrl- or sh Il6r -transduced AML cells ( n = 10–20). (J) Schematic model of the findings of this study. Osteoblastic mTORC1 signaling enhances IL-6 production, which activates JAK/STAT3 signaling to promote cell proliferation and inhibit apoptosis in undifferentiated AML cells, driving AML progression. All mice used in this study were male. n.s., not significant. ∗ p < 0.05, ∗∗∗ p < 0.001, and # p < 0.05. Error bars show the standard deviation.
Article Snippet:
Techniques: Cell Culture, Expressing, Knockdown, Standard Deviation